SEP 10, 2026 · PHASE 1 TRIAL
A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC
ClinicalTrials.gov
Phase 1 study in early development stage with no results yet reported; designed to assess safety, tolerability, and dose-finding in a small patient population with EGFR-mutant NSCLC and HNSCC.
Reported
Planned enrollment110
Study phasePhase 1
Primary outcome measure 1Evaluation of the safety and tolerability o…